Skip to main content

Table 3 Summary of adverse events

From: Addition of nucleoside analogues to peg-IFNα-2a enhances virological response in chronic hepatitis B patients without early response to peg-IFNα-2a: a randomized controlled trial

Adverse events

Peg-IFNα-2a

(n = 43)

Combination groups (n = 95)

Fatigue and muscle ache

36 (83.7%)

76 (80%)

Fever

30 (70%)

70 (73.7%)

Thrombocytopenia

22 (51.2%)

47 (49.5%)

Anemia

16 (37.2%)

36 (37.9%)

Neutropenia

14 (32.6%)

33 (34.7%)

Loss of appetite

15 (34.9%)

30 (31.6%)

Hair Loss

10 (23.3%)

24 (25.3%)

Abnormal blood glucose

2 (4.7%)

5 (5.3%)

Rash

2 (4.7%)

3 (3.2%)

Hypothyroidism

1 (2.3%)

1 (1.1)

  1. Data were summarized as n (%) for given adverse events in each group
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us